Descrizione del progetto
Una nuova tecnologia di imaging monitora la risposta al trattamento nella malattia infiammatoria intestinale
Le malattie infiammatorie intestinali (MII), tra cui il morbo di Crohn e la colite ulcerosa, sono correlate all’infiammazione cronica del tratto gastrointestinale. Le MII causano una morbilità significativa per milioni di persone in tutto il mondo e impongono regimi di trattamento complessi che comportano costi medici rilevanti. L’obiettivo principale del progetto msGUIDE, finanziato dal CEI, è supportare la gestione personalizzata della malattia sviluppando una tecnologia di imaging altamente sensibile, in grado di quantificare la distribuzione dei farmaci nell’intestino dei pazienti affetti da MII. Tale tecnologia rivoluzionaria può offrire un monitoraggio quantitativo della risposta al trattamento nei pazienti affetti da MII, supportando decisioni personalizzate e basate sull’evidenza per migliorare i risultati clinici.
Obiettivo
Inflammatory bowel diseases (IBD) are chronic relapsing inflammatory disorders of the gastrointestinal tract affecting 2.5 Mil. patients in Europe alone. The majority of newly diagnosed patients are in adolescence or early adulthood and in the midst of their family life, career, and social development. Though not life-threatening, the disease comes with significant morbidity and complex treatment strategies and is associated with a high social burden and medical costs. msGUIDE aims to revolutionize IBD treatment by offering high-performance insight into local drug distribution and concentrations that can lead personalized medicine in IBD patients and early drug development through identifying specific targeted cells of drugs, elucidating the individual phenotype and thereby patient stratification. This will be achieved by reinvigorating endoscopy to overcome major challenges for medical application. The goal of msGUIDE is to develop a highly sensitive novel imaging technology consisting of a Near-Infrared Fluorescence and Reflectance Multispectral Imaging (NIR-FRMI) unit integrated into a never before seen High-definition White Light Endoscope (HD-WLE). The aim is to quantify drug distribution and concentration and identify the individual drug target cells in the gut. With this groundbreaking system we offer an operatorindependent endoscopic method to establish the optimal dose and to monitor the treatment response in IBD patients in realtime. This will allow for an individual, precise and quantitative diagnosis leading to a more personalized, targeted and thus more effective treatment in IBD and common diseases in general.
Campo scientifico
Programma(i)
Invito a presentare proposte
HORIZON-EIC-2021-PATHFINDEROPEN-01
Vedi altri progetti per questo bandoMeccanismo di finanziamento
HORIZON-EIC - HORIZON EIC GrantsCoordinatore
85764 Neuherberg
Germania